Christian Carrwik1, Ulf Stenevi. 1. Department of Ophthalmology, Sahlgrenska University Hospital, Mölndal, Gothenburg, Sweden.
Abstract
PURPOSE: This paper reviews current knowledge about the pathogenesis, clinical manifestations and treatment of lattice corneal dystrophy, gelsolin type (LCD2, Meretoja's syndrome). METHODS: Material is derived from literature searches, a case study of a Finnish patient living in Sweden, and interviews in Helsinki with Professor Ahti Tarkkanen and Dr Sari Kiuru-Enari, both of whom have extensive first-hand experience in treating patients with the disease. RESULTS: The disease is now reported from several countries in Europe, as well as Japan, the USA and Iran. Treatment is symptomatic and is based on eye lubrication combined with rigorous monitoring of intraocular pressure to reduce corneal haze and postpone the need for keratoplasty. When systemic symptoms occur, the ophthalmologist should consult other specialists. CONCLUSIONS: The disease is probably under-reported and is almost certainly to be found in more countries, including Sweden. Every ophthalmologist should be vigilant and consider this diagnosis when discovering a corneal lattice dystrophy, especially because the disease is an inherited, lifelong chronic condition with systemic symptoms.
PURPOSE: This paper reviews current knowledge about the pathogenesis, clinical manifestations and treatment of lattice corneal dystrophy, gelsolin type (LCD2, Meretoja's syndrome). METHODS: Material is derived from literature searches, a case study of a Finnish patient living in Sweden, and interviews in Helsinki with Professor Ahti Tarkkanen and Dr Sari Kiuru-Enari, both of whom have extensive first-hand experience in treating patients with the disease. RESULTS: The disease is now reported from several countries in Europe, as well as Japan, the USA and Iran. Treatment is symptomatic and is based on eye lubrication combined with rigorous monitoring of intraocular pressure to reduce corneal haze and postpone the need for keratoplasty. When systemic symptoms occur, the ophthalmologist should consult other specialists. CONCLUSIONS: The disease is probably under-reported and is almost certainly to be found in more countries, including Sweden. Every ophthalmologist should be vigilant and consider this diagnosis when discovering a corneal lattice dystrophy, especially because the disease is an inherited, lifelong chronic condition with systemic symptoms.
Authors: Adam J Loavenbruck; Wolfgang Singer; Michelle L Mauermann; Paola Sandroni; P James B Dyck; Morie Gertz; Christopher J Klein; Phillip A Low Journal: Ann Neurol Date: 2016-07-25 Impact factor: 10.422
Authors: Ruchi Shah; Cynthia Amador; Kati Tormanen; Sean Ghiam; Mehrnoosh Saghizadeh; Vaithi Arumugaswami; Ashok Kumar; Andrei A Kramerov; Alexander V Ljubimov Journal: Exp Eye Res Date: 2021-01-21 Impact factor: 3.467
Authors: Jesus Cabral-Macias; Leopoldo A Garcia-Montaño; Mario Pérezpeña-Díazconti; Marisa-Cruz Aguilar; Guillermo Garcia; Carlos I Vencedor-Meraz; Enrique O Graue-Hernandez; Oscar F Chacón-Camacho; Juan C Zenteno Journal: Mol Vis Date: 2020-05-02 Impact factor: 2.367
Authors: Maja Potrč; Marija Volk; Matteo de Rosa; Jože Pižem; Nataša Teran; Helena Jaklič; Aleš Maver; Brigita Drnovšek-Olup; Michela Bollati; Katarina Vogelnik; Alojzija Hočevar; Ana Gornik; Vladimir Pfeifer; Borut Peterlin; Marko Hawlina; Ana Fakin Journal: Int J Mol Sci Date: 2021-01-22 Impact factor: 5.923